Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Carcinoma Transitional Cell/*drug therapy/pathology Clinical Trials Phase II as Topic Clinical Trials Phase III as Topic Humans Neoplasm Metastasis Neoplasm Staging Practice Guidelines as Topic Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/*drug therapy/pathology Immune checkpoint inhibitors Platinum-based chemotherapy Survival outcomes Treatment guidelines Urothelial carcinoma funded this work. MK PK and SD are employees of Evidera.

Antineoplastic Agents/*therapeutic use Biomarkers Tumor/*blood Humans Male Neoadjuvant Therapy/*methods Prognosis Urinary Bladder Neoplasms/blood/drug therapy/*pathology Biomarkers Bladder cancer Nac Neoadjuvant chemotherapy Systematic review Ucb

Cystoscopy/*methods Feasibility Studies Humans Liquid Biopsy/methods Sensitivity and Specificity *Spectrum Analysis Raman Urinary Bladder/diagnostic imaging/*pathology Urinary Bladder Neoplasms/*diagnosis/pathology/urine Urine/cytology Bladder cancer Raman spectroscopy diagnosis meta-analysis optical

*Clinical Protocols *Cystectomy/methods *Enhanced Recovery After Surgery Humans Time Factors Treatment Outcome Urinary Bladder Neoplasms/*surgery Cystectomy Eras Fast track Meta-analysis Protocol Systematic review evidence-based medicine

Carcinoma Transitional Cell/*classification/*genetics/mortality Humans Predictive Value of Tests Survival Rate Treatment Outcome Urinary Bladder Neoplasms/*classification/*genetics/mortality Bladder cancer Molecular classification Molecular subtype Prognosis Progression Urothelial carcinoma

Humans Lymphocytes/*pathology Neutrophils/*pathology *Preoperative Care Prognosis Publication Bias Survival Analysis Urinary Bladder Neoplasms/*immunology/*surgery

Biomarkers Tumor/*analysis Carcinoma Transitional Cell/*chemistry/*drug therapy Humans Neoadjuvant Therapy Prognosis Urinary Bladder Neoplasms/*chemistry/*drug therapy Biomarkers Nac Neoadjuvant systemic therapy Ucb bladder cancer systematic review

Carcinoma Transitional Cell/*drug therapy Humans Prognosis Receptors Fibroblast Growth Factor/*antagonists & inhibitors Urinary Bladder Neoplasms/*drug therapy Bladder cancer Fgfr FGFR inhibitors Fgfr3 Progression Urothelial carcinoma

Carcinoma in Situ/*diagnosis/*therapy Humans Treatment Outcome Urinary Bladder Neoplasms/*diagnosis/*therapy Bladder cancer Carcinoma in situ Non–muscle-invasive bladder cancer

Adjuvants Immunologic/*administration & dosage Administration Intravesical BCG Vaccine/*administration & dosage Humans *Lymphocytes Tumor-Infiltrating Treatment Outcome Urinary Bladder Neoplasms/*drug therapy/immunology/*pathology

Adjuvants Immunologic/therapeutic use BCG Vaccine/therapeutic use Evidence-Based Medicine Humans Neoplasm Invasiveness Neoplasm Recurrence Local/*therapy Treatment Outcome Urinary Bladder Neoplasms/pathology/*therapy Bacillus Calmette-Guerin unresponsive Bladder preservation therapy Bladder sparing Non–muscle-invasive bladder cancer

Aged Cystectomy/adverse effects/*methods/statistics & numerical data Humans Male Middle Aged Postoperative Complications Quality of Life Randomized Controlled Trials as Topic Robotic Surgical Procedures/adverse effects/*methods/statistics & numerical data Treatment Outcome Urinary Bladder Neoplasms/*surgery

Anti-Bacterial Agents/therapeutic use Antibiotic Prophylaxis Humans Meta-Analysis as Topic Postoperative Complications/drug therapy Systematic Reviews as Topic *Urinary Bladder Neoplasms/drug therapy/surgery *Urinary Tract Infections/drug therapy/prevention & control Antibiotic resistance Antibiotics Antimicrobial stewardship Bacteriuria Endourological surgery Guideline Recommendation Transitional cell carcinoma Urothelium cell carcinoma

经尿道膀胱肿瘤切除术 荟萃分析 单极 双极 膀胱癌

Antineoplastic Agents Immunological/*therapeutic use Carcinoma Transitional Cell/*drug therapy Humans Immunotherapy/*adverse effects/methods Network Meta-Analysis Salvage Therapy/*methods Urinary Bladder Neoplasms/*drug therapy Rct Uc Ucb adverse events chemotherapy immunotherapy network meta-analyses second-line

*Antibiotic Prophylaxis Bacteriuria/*prevention & control Humans Postoperative Complications/*prevention & control Urinary Bladder Neoplasms/*surgery Urinary Tract Infections/*prevention & control antibiotic prophylaxis bacteriuria carcinoma transitional cell health planning guidelines systematic review

Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Chemotherapy Adjuvant/methods Cisplatin/therapeutic use Clinical Decision-Making/methods *Cystectomy Disease-Free Survival Female Humans Male Neoadjuvant Therapy/methods Neoplasm Recurrence Local/*epidemiology/pathology/prevention & control Neoplasm Staging Patient Selection *Sex Factors Urinary Bladder/pathology/surgery Urinary Bladder Neoplasms/mortality/pathology/*therapy Adjuvant chemotherapy Bladder cancer Gender Meta-analysis Neoadjuvant chemotherapy

Administration Intravesical Antibiotics Antineoplastic/*administration & dosage Antimetabolites Antineoplastic/*administration & dosage Deoxycytidine/administration & dosage/*analogs & derivatives Humans Mitomycin/*administration & dosage Neoplasm Invasiveness Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/*drug therapy/pathology Gemcitabine Bladder cancer Meta-analysis Mitomycin Systematic evaluation

Humans Quality of Life Retrospective Studies *Sarcopenia/epidemiology/etiology *Urinary Bladder Neoplasms/complications/epidemiology Bladder cancer Prevalence Sarcopenia Systematic review

Adult Caffeine/*adverse effects Central Nervous System Stimulants/adverse effects Coffee/*adverse effects Cytochrome P-450 CYP1A2 Dose-Response Relationship Drug Female Humans Male Middle Aged Risk Factors Smoking/*adverse effects Urinary Bladder Neoplasms/*etiology Bladder cancer Coffee consumption Cohort study Dose–response analyses Smoking